South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Purpose: Pirfenidone and nintedanib are two novel antifibrotic agents licensed for the treatment IPF. Prior to being approved for use in England for patients with FVC >50% and <80%, these were made available for all IPF patients under the Mild Patient Program (MPP) and Patient In Need Scheme (...

Full description

Saved in:
Bibliographic Details
Main Authors: Shaney L. Barratt (Author), Sarah Mulholland (Author), Khaled Al Jbour (Author), Henry Steer (Author), Markus Gutsche (Author), Noeleen Foley (Author), Rajiv Srivastava (Author), Charles Sharp (Author), Huzaifa I. Adamali (Author)
Format: Book
Published: Frontiers Media S.A., 2018-12-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items